http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 17 Aug 2026 08:02:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Acurx+gets+FDA+conditional+brand+name+acceptance+for+CDI+drug/26935127.html <p>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced that the FDA has conditionally accepted the proposed brand name CIFBEZY for ibezapolstat, its antibiotic candidate for <em>Clostridioides difficile</em> infection (CDI). The U.S. Patent and Trademark Office (USPTO) has also allowed the trademark application for the name.</p><p>According to a company statement, the name CIFBEZY was developed through a screening process involving branding experts, prescribers, pharmacists, and linguists, as evaluated by the FDA's Division of Medication Error Prevention and Analysis. A request for final FDA review and approval of the brand name is required at the time of a New Drug Application (NDA) submission.</p><p>The USPTO's http://www.streetinsider.com/Corporate+News/Acurx+gets+FDA+conditional+brand+name+acceptance+for+CDI+drug/26935127.html Mon, 17 Aug 2026 08:02:36 -0400 ACXP http://www.streetinsider.com/FDA/Acurx+gets+FDA+conditional+brand+name+acceptance+for+CDI+drug/26935127.html <p>Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced that the FDA has conditionally accepted the proposed brand name CIFBEZY for ibezapolstat, its antibiotic candidate for <em>Clostridioides difficile</em> infection (CDI). The U.S. Patent and Trademark Office (USPTO) has also allowed the trademark application for the name.</p><p>According to a company statement, the name CIFBEZY was developed through a screening process involving branding experts, prescribers, pharmacists, and linguists, as evaluated by the FDA's Division of Medication Error Prevention and Analysis. A request for final FDA review and approval of the brand name is required at the time of a New Drug Application (NDA) submission.</p><p>The USPTO's http://www.streetinsider.com/FDA/Acurx+gets+FDA+conditional+brand+name+acceptance+for+CDI+drug/26935127.html Mon, 17 Aug 2026 08:02:36 -0400 ACXP http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html <div class="xn-content"> <ul type="disc"><li>The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO</li><li>These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3 registration program for both the acute treatment and reduction of recurrence in <i>C. difficile</i> Infection (CDI)</li><li>As required, a request for final FDA review and approval of the brand name will be submitted at time of marketing application for the NDA</li></ul><p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. http://www.streetinsider.com/PRNewswire/Acurx+Pharmaceuticals+Receives+FDA+Conditional+Acceptance+and+USPTO+Trademark+Allowance+for+the+Company%27s+Brand+Name+for+Ibezapolstat/26935103.html Mon, 17 Aug 2026 08:01:00 -0400 A.01908724 A.06822034 A.14320728 ACXP O.20026344 O.20250741 O.20988509 O.51068808 http://www.streetinsider.com/Earnings/Acurx+Pharmaceuticals+%28ACXP%29+Tops+Q2+EPS+by+4c/26924453.html <p>Acurx Pharmaceuticals (NASDAQ: ACXP) reported Q2 EPS of ($0.53), $0.04 better than the analyst estimate of ($0.57).</p><p>For earnings history and earnings-related data on Acurx Pharmaceuticals (ACXP) <a href="http://www.streetinsider.com/ec_earnings.php?q=ACXP">click here</a>.</p> http://www.streetinsider.com/Earnings/Acurx+Pharmaceuticals+%28ACXP%29+Tops+Q2+EPS+by+4c/26924453.html Fri, 14 Aug 2026 07:02:22 -0400 ACXP http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808 http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ny.staand" idsrc="xmltag.org" >STATEN ISLAND, N.Y.</location></span>, <span class="legendSpanClass"><chron>Aug. 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ACXP" idsrc="xmltag.org" >Acurx Pharmaceuticals, Inc.</span> (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and operational results for the second quarter ended <chron>June 30, 2026</chron>.  </p> <p>Highlights of the second quarter ended <chron>June 30, 2026</chron>, or in some cases shortly thereafter, include:</p><ul type="disc"><li>In <chron>April 2026</chron>, the Company announced the closing of a registered direct offering of 825,085 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price http://www.streetinsider.com/Press+Releases/Acurx+Pharmaceuticals%2C+Inc.+Reports+Second+Quarter+2026+results+and+provides+business+update/26924435.html Fri, 14 Aug 2026 07:01:00 -0400 A.06822034 A.20726076 A.50201572 ACXP O.12478371 O.20026344 O.30702215 O.51068808